Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers
Aarif Siddiqui(Friedrich-Alexander-Universität Erlangen-Nürnberg), Paolo Ceppi(University of Southern Denmark), Paradesi Naidu Gollavilli(Friedrich-Alexander-Universität Erlangen-Nürnberg), Dick Pluim, Annemarie Schwab(Friedrich-Alexander-Universität Erlangen-Nürnberg), Pelin G. Ersan(Bilkent University), Özgür Şahin(MUSC Hollings Cancer Center), Baek Kim(University of Rochester), Mallika Ramakrishnan, Si’Ana A. Coggins(Henry M. Jackson Foundation), Özge Saatci(Medical University of South Carolina), Caterina Marchiò(Candiolo Cancer Institute), Laura Annaratone(Candiolo Cancer Institute), Irfan A. Asangani(Penn Center for AIDS Research), Suhail Ahmed Kabeer Rasheed(Duke-NUS Medical School), Maria Eleni Vazakidou(Friedrich-Alexander-Universität Erlangen-Nürnberg), Jan H.M. Schellens(Utrecht University)
Cited by 53
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|416
The role of CD95 and CD95 ligand in cancer
|Cell Death and Differentiation|2015|338